Literature DB >> 9226208

Behavioral effects of liothyronine (L-T3) in children with attention deficit hyperactivity disorder in the presence and absence of resistance to thyroid hormone.

R E Weiss1, M A Stein, S Refetoff.   

Abstract

Evidence that the thyroid may play a role in the pathogenesis of attention deficit hyperactivity disorder (ADHD) comes from observations that 48% to 73% of children with the syndrome of resistance to thyroid hormone (RTH) have ADHD. Casual observations in subjects with RTH have suggested that treatment with thyroid hormone may improve the symptoms of ADHD. The aim of this study was to determine whether thyroid hormone has a beneficial effect on the behavior of children with RTH. A prospective, randomized, double-blinded, placebo-controlled, cross-over study was conducted to evaluate the effect of the rapid acting thyroid hormone, liothyronine (L-T3), on the behavior of 8 children with ADHD + RTH, and 9 children with ADHD and normal thyroid function (ADHD Only). Parent and teacher ratings of hyperactivity (Conners scale) and a computerized continuous performance test (CPT) were used as objective measures of hyperactivity, attention and impulsivity. L-T3 had no effect on Conners Hyperactivity Index in 7 of 9 children with ADHD Only; it caused improvement and deterioration in 1 subject each. In contrast, the rating in 5 of 8 subjects with ADHD + RTH showed improvement, whereas 3 of 8 subjects remained unchanged. L-T3 was associated with increased commission errors in 5 of 8 children with ADHD Only and decreased commission errors in 4 of 7 with ADHD + RTH. In children with RTH and ADHD, particularly those that exhibit hyperactivity, L-T3 in supraphysiological doses may be beneficial in reducing hyperactivity and impulsivity. In the majority of children with ADHD who do not have RTH, L-T3 treatment has no effect or may be detrimental.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226208     DOI: 10.1089/thy.1997.7.389

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

Review 1.  Resistance to thyroid hormone.

Authors:  R E Weiss; S Refetoff
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

2.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

3.  Endocrine and neuropsychological assessment in a child with a novel mutation of thyroid hormone receptor: response to 12-month triiodothyroacetic acid (TRIAC) therapy.

Authors:  P Torre; M Bertoli; S Di Giovanni; S Scommegna; C Conte; G Novelli; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2005 Jul-Aug       Impact factor: 4.256

Review 4.  EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.

Authors:  A C Gore; V A Chappell; S E Fenton; J A Flaws; A Nadal; G S Prins; J Toppari; R T Zoeller
Journal:  Endocr Rev       Date:  2015-11-06       Impact factor: 19.871

5.  Successful every-other-day liothyronine therapy for severe resistance to thyroid hormone beta with a novel THRB mutation; case report.

Authors:  Yoshihiro Maruo; Asami Mori; Yoriko Morioka; Chihiro Sawai; Yu Mimura; Katsuyuki Matui; Yoshihiro Takeuchi
Journal:  BMC Endocr Disord       Date:  2016-01-12       Impact factor: 2.763

6.  Resistance to thyroid hormone-beta co-existing with partially empty sella in a Jordanian male.

Authors:  Ohoud Al Mohareb; Mussa H AlMalki; O Thomas Mueller; Imad Brema
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-12-05

Review 7.  Resistance to Thyroid Hormone Beta: A Focused Review.

Authors:  Theodora Pappa; Samuel Refetoff
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-31       Impact factor: 5.555

8.  Low striatal T3 is implicated in inattention and memory impairment in an ADHD mouse model overexpressing thyroid hormone-responsive protein.

Authors:  Raly James Perez Custodio; Mikyung Kim; Leandro Val Sayson; Hyun Jun Lee; Darlene Mae Ortiz; Bung-Nyun Kim; Hee Jin Kim; Jae Hoon Cheong
Journal:  Commun Biol       Date:  2021-09-20

9.  A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation.

Authors:  Hazuki Komahashi-Sasaki; Norio Yasui-Furukori; Ryo Maehara; Chie Hasegawa; Kazutaka Shimoda
Journal:  Neuropsychopharmacol Rep       Date:  2022-06-24

10.  Why most biomedical findings echoed by newspapers turn out to be false: the case of attention deficit hyperactivity disorder.

Authors:  François Gonon; Jan-Pieter Konsman; David Cohen; Thomas Boraud
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.